Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 Monotherapy or Combination in Early-Stage or Locally Advanced NSCLC
NCT07489066Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Modality
- Bispecific Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of PF-08634404 in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Jun 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07489066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489066.